Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models.

ABSTRACT: A significant challenge in the development of long-acting injectable drug formulations, especially for anti-infective agents, is delivering an efficacious dose within a tolerable injection volume. Co-administration of the extracellular matrix-degrading enzyme hyaluronidase can increase maximum tolerable injection volumes but is untested for this benefit with long-acting injectable formulations. One concern is that hyaluronidase could potentially alter the tissue response surrounding an injection depot, a response known to be important for drug release kinetics of long-acting injectable formulations. The objective of this pilot study was to evaluate the impact of co-administration of hyaluronidase on the drug release kinetics, pharmacokinetic profiles, and injection site histopathology of t

SUBMITTER: Pertinez H 

PROVIDER: S-EPMC10942359 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature